The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Ketogenic diets for drug-resistant epilepsy
Open accessAbstract
BACKGROUND: Ketogenic diets (KDs) are high in fat and low in carbohydrates and have been suggested to reduce seizure frequency in people with epilepsy. Such diets may be beneficial for children with drug-resistant epilepsy. This is an update of a review first published in 2003, and last updated in 2018. OBJECTIVES: To assess the effects of ketogenic diets for people with drug-resistant epilepsy. SEARCH METHODS: For this update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 26 April 2019) on 29 April 2019. The Cochrane Register of Studies includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and randomised controlled trials (RCTs) from Embase, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We checked the reference lists of retrieved studies for additional relevant studies. SELECTION CRITERIA: RCTs or quasi-RCTs of KDs for people of any age with drug-resistant epilepsy. DATA COLLECTION AND ANALYSIS: Two review authors independently applied predefined criteria to extract data and evaluated study quality. We assessed the outcomes: seizure freedom, seizure reduction (50% or greater reduction in seizure frequency), adverse effects, cognition and behaviour, quality of life, and attrition rate. We incorporated a meta-analysis. We utilised an intention-to-treat (ITT) population for all primary analyses. We presented the results as risk ratios (RRs) with 95% confidence intervals (CIs). MAIN RESULTS: We identified 13 studies with 932 participants; 711 children (4 months to 18 years) and 221 adults (16 years and over). We assessed all 13 studies to be at high risk of performance and detection bias, due to lack of blinding. Assessments varied from low to high risk of bias for all other domains. We rated the evidence for all outcomes as low to very low certainty. Ketogenic diets versus usual care for children Seizure freedom (RR 3.16, 95% CI 1.20 to 8.35; P = 0.02; 4 studies, 385 participants; very low-certainty evidence) and seizure reduction (RR 5.80, 95% CI 3.48 to 9.65; P < 0.001; 4 studies, 385 participants; low-certainty evidence) favoured KDs (including: classic KD, medium-chain triglyceride (MCT) KD combined, MCT KD only, simplified modified Atkins diet (MAD) compared to usual care for children. We are not confident that these estimated effects are accurate. The most commonly reported adverse effects were vomiting, constipation and diarrhoea for both the intervention and usual care group, but the true effect could be substantially different (low-certainty evidence). Ketogenic diet versus usual care for adults In adults, no participants experienced seizure freedom. Seizure reduction favoured KDs (MAD only) over usual care but, again, we are not confident that the effect estimated is accurate (RR 5.03, 95% CI 0.26 to 97.68; P = 0.29; 2 studies, 141 participants; very low-certainty evidence). Adults receiving MAD most commonly reported vomiting, constipation and diarrhoea (very low-certainty evidence). One study reported a reduction in body mass index (BMI) plus increased cholesterol in the MAD group. The other reported weight loss. The true effect could be substantially different to that reported. Ketogenic diet versus ketogenic diet for children Up to 55% of children achieved seizure freedom with a classical 4:1 KD after three months whilst up to 85% of children achieved seizure reduction (very low-certainty evidence). One trial reported a greater incidence of seizure reduction with gradual-onset KD, as opposed to fasting-onset KD. Up to 25% of children were seizure free with MAD and up to 60% achieved seizure reduction. Up to 25% of children became seizure free with MAD and up to 60% experienced seizure reduction. One study used a simplified MAD (sMAD) and reported that 15% of children gained seizure freedom rates and 56% achieved seizure reduction. We judged all the evidence described as very low certainty, thus we are very unsure whether the results are accurate. The most commonly reported adverse effects were vomiting, constipation and diarrhoea (5 studies, very low-certainty evidence). Two studies reported weight loss. One stated that weight loss and gastrointestinal disturbances were more frequent, with 4:1 versus 3:1 KD, whilst one reported no difference in weight loss with 20 mg/d versus 10 mg/d carbohydrates. In one study, there was a higher incidence of hypercalcuria amongst children receiving classic KD compared to MAD. All effects described are unlikely to be accurate. Ketogenic diet versus ketogenic diet for adults One study randomised 80 adults (aged 18 years and over) to either MAD plus KetoCal during the first month with MAD alone for the second month, or MAD alone for the first month followed by MAD plus KetoCal for the second month. No adults achieved seizure freedom. More adults achieved se
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial
Neal, E. G., Chaffe, H., Schwartz, R. H., Lawson, M. S., Edwards, N., Fitzsimmons, G., Whitney, A., & Cross, J. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70092-9 · Cited by 1,224
Kirkham, J. J., Dwan, K. M., Altman, D. G., Gamble, C., Dodd, S., Smyth, R., & Williamson, P. R. (2010) · BMJ · doi:10.1136/bmj.c365 · Cited by 1,133
Chang, B. S., & Lowenstein, D. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022308 · Cited by 731
The effect of ketonemia on the course of epilepsy
Wilder, R. M. (1921) · Mayo Clinic Proceedings · Cited by 603
Epilepsy: Frequency, causes and consequences
Messenheimer, J. A. (1991) · Journal of Epilepsy · doi:10.1016/0896-6974(91)90095-z · Cited by 562
Anticonvulsant Mechanisms of the Ketogenic Diet
Bough, K. J., & Rho, J. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00915.x · Cited by 523
Risk factors for sudden unexpected death in epilepsy: a case control study
Nilsson, L., Farahmand, B., Persson, P.-G., Thiblin, I., & Tomson, T. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05114-9 · Cited by 522
SODIUM DIPHENYL HYDANTOINATE IN THE TREATMENT OF CONVULSIVE DISORDERS
MERRITT, H. H. (1938) · Journal of the American Medical Association · doi:10.1001/jama.1938.02790380010004 · Cited by 457
Cited by
Ketone bodies: from enemy to friend and guardian angel
Kolb, H., Kempf, K., Röhling, M., Lenzen-Schulte, M., Schloot, N. C., & Martin, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-02185-0 · Cited by 361
The metabolic basis of epilepsy
Rho, J. M., & Boison, D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00651-8 · Cited by 295
The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 269
Ułamek-Kozioł, M., Czuczwar, S. J., Januszewski, S., & Pluta, R. (2019) · Nutrients · doi:10.3390/nu11102510 · Cited by 266
Ketogenic diets and chronic disease: weighing the benefits against the risks
Crosby, L., Davis, B., Joshi, S., Jardine, M., Paul, J., Neola, M., & Barnard, N. D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.702802 · Cited by 229
Metadata
- Authors
- Martin-McGill, K. J., Bresnahan, R., Levy, R. G., & Cooper, P. N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2020-06-24
- Volume
- 2020
- Issue
- 6
- Pages
- CD001903-CD001903
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2900384992
- Cited by
- 402
- References
- 45
- FWCI
- 25.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketogenic diets for drug-resistant epilepsy. https://app.cochat.ai/papers/10.1002/14651858.cd001903.pub5
- The paper
- Martin-McGill, K. J., Bresnahan, R., Levy, R. G., & Cooper, P. N. (2020). Ketogenic diets for drug-resistant epilepsy. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001903.pub5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.